Cadence Healthcare Ventures — Full Portfolio
4 tracked investments · listed companies and verified rows first
Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).
BiotechHealthtechMedical DevicesAustin, US
Adam Berman(Executive Officer, Director)Jacob Kriegel(Executive Officer, Director)Avni Patel(Executive Officer, Director)Christopher Alex Arevalos(Executive Officer, Director)Albertien Greijdanus(Executive Officer, Director)
BoardGeoff Pardo(Director)
Board seatChristopher Kaster· per SEC Form D · $91.4M raise · filed Jan 2025
Co-investorsBroadview VenturesRiverVest Venture PartnersTMC Venture FundGilde HealthcareGilmartin Capital LLCS3 Ventures+1 more
BiotechIowa City, US
Steven Richard Mickelsen(Executive Officer, Director, Promoter)Raju Viswanathan(Executive Officer)David Jacques(Executive Officer)Allan Zingeler(Executive Officer, Director)
BoardDavid Booth(Director)Howard Dittrich(Director)
Board seatChristopher Kaster· per SEC Form D · $12M raise · filed Aug 2018
Co-investorsDeerfield Management Company
HealthtechBelmont, US
Robert T Chang(Executive Officer, Director)
BoardDouglas Koo(Director)
Board seatChristopher Kaster· per SEC Form D · $12.8M raise · filed Mar 2016
SetPoint Medical develops an FDA-approved implantable neurostimulation device that stimulates the vagus nerve to reduce inflammation, offering a device-based treatment for adults with moderate-to-severe rheumatoid arthritis who have not responded to biologic or targeted synthetic drugs.
BiotechHealthtechMedical DevicesValencia, US
Murthy Simhambhatla(CEO)David Chernoff(Chief Medical Officer (MD))Yaakov Levine(PhD)Rohan Seth(Executive Officer)
BoardBlake Wu(Director)Juan-Pablo Mas(Director)
Board seatChristopher Kaster· per SEC Form D · $15.1M raise · filed Sep 2015
Co-investorsAlly Bridge GroupNew Enterprise Associates (NEA)Norwest Venture PartnersTopspin PartnersCatalio Capital Management, LPCitta Capital+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.